Wedmont Private Capital Purchases 7,564 Shares of Johnson & Johnson $JNJ

Wedmont Private Capital boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 22.2% in the third quarter, HoldingsChannel.com reports. The fund owned 41,616 shares of the company’s stock after acquiring an additional 7,564 shares during the quarter. Wedmont Private Capital’s holdings in Johnson & Johnson were worth $10,674,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Silver Coast Investments LLC lifted its holdings in shares of Johnson & Johnson by 3.8% during the second quarter. Silver Coast Investments LLC now owns 1,066 shares of the company’s stock worth $271,000 after purchasing an additional 39 shares during the period. Townsend Asset Management Corp NC ADV raised its position in Johnson & Johnson by 0.6% during the 2nd quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company’s stock worth $1,630,000 after buying an additional 39 shares during the last quarter. Triumph Capital Management raised its position in Johnson & Johnson by 1.6% during the 2nd quarter. Triumph Capital Management now owns 2,531 shares of the company’s stock worth $643,000 after buying an additional 39 shares during the last quarter. Kwmg LLC lifted its stake in Johnson & Johnson by 1.7% during the 3rd quarter. Kwmg LLC now owns 2,383 shares of the company’s stock valued at $631,000 after acquiring an additional 39 shares during the period. Finally, Denali Advisors LLC boosted its holdings in shares of Johnson & Johnson by 1.2% in the 2nd quarter. Denali Advisors LLC now owns 3,305 shares of the company’s stock valued at $839,000 after acquiring an additional 40 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer Taubert sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president directly owned 16,994 shares of the company’s stock, valued at approximately $4,367,458. The trade was a 48.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 87,569 shares of company stock worth $23,064,544. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $261.27 on Friday. The company has a market capitalization of $629.64 billion, a PE ratio of 30.27, a price-to-earnings-growth ratio of 2.60 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The company’s fifty day moving average price is $265.83 and its 200 day moving average price is $249.01. Johnson & Johnson has a 1 year low of $184.66 and a 1 year high of $281.07.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. During the same quarter in the previous year, the company earned $2.77 earnings per share. The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, research analysts predict that Johnson & Johnson will post 11.18 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were issued a $1.34 dividend. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio is presently 62.11%.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported two-year Phase 3 ICONIC-LEAD results for ICOTYDE (icotrokinra), its targeted oral IL-23 receptor peptide for moderate-to-severe plaque psoriasis. Nearly three-quarters of adults and adolescents achieved clear or almost clear skin at two years, with responses sustained and a favorable safety profile. The results strengthen the potential of ICOTYDE as a future growth product and were presented at a dermatology meeting. Johnson & Johnson ICOTYDE two-year psoriasis data
• Positive Sentiment: Guggenheim reaffirmed a Buy rating, while Morgan Stanley also issued a Buy rating. The positive analyst view reflects JNJ’s diversified healthcare portfolio, drug launches and defensive dividend appeal. Guggenheim reaffirms Buy rating
• Positive Sentiment: Several investment commentaries continue to present JNJ as a dividend-focused healthcare holding, emphasizing its long record of dividend growth and relatively dependable cash generation compared with higher-yielding but riskier peers. Healthcare Dividend Aristocrats
• Neutral Sentiment: JNJ is approaching its third-quarter earnings report with expectations for continued strength in pharmaceuticals and newer product launches. Investors will focus on revenue growth, guidance and the pace of Stelara-related sales erosion.
• Negative Sentiment: Analysts warn that biosimilar competition for Stelara and challenges in the MedTech business could weigh on near-term growth, limiting the impact of otherwise strong drug performance. J&J stock ahead of Q3 earnings
• Negative Sentiment: Upcoming patent expirations for Imbruvica and Darzalex create a longer-term “patent cliff” risk, potentially pressuring pharmaceutical revenue unless pipeline products and acquisitions offset lost exclusivity. J&J patent cliff analysis
• Negative Sentiment: Boston Scientific has sued JNJ subsidiary Atraverse over alleged patent infringement involving the Hotwire cardiology device, seeking damages and an injunction. The financial impact is uncertain but adds legal and competitive risk to the MedTech segment. Boston patent lawsuit against J&J subsidiary

Wall Street Analysts Forecast Growth

JNJ has been the subject of several recent research reports. Citigroup raised their target price on shares of Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a report on Monday. HSBC increased their price target on Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Weiss Ratings upgraded Johnson & Johnson from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday. Freedom Capital upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 16th. Finally, Morgan Stanley raised their target price on Johnson & Johnson from $284.00 to $294.00 and gave the stock an “overweight” rating in a report on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $276.22.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.